GLP-1s Reduced Heart Failure Severity by 40%

Harvard and Brigham researchers found that GLP-1 medications improved heart failure with preserved ejection fraction by 40% — a condition that has historically had almost no effective treatments.

Heart failure with preserved ejection fraction (HFpEF) is one of medicine's most frustrating conditions. The heart muscle becomes so stiff that the ventricle can't fill properly, leading to fluid buildup, breathlessness, and fatigue. Unlike other forms of heart failure, HFpEF has had very few effective treatments. Until now. Harvard Gazette

Why This Matters

HFpEF accounts for roughly half of all heart failure cases — affecting millions of Americans. Unlike heart failure with reduced ejection fraction (HFrEF), which has several effective drug classes, HFpEF has been notoriously difficult to treat. Patients often cycle through medications with limited benefit, facing progressive disability and frequent hospitalizations.

Nils Krüger, an instructor at Harvard Medical School and Brigham and Women's Hospital, and his research team investigated GLP-1 medications' effects across multiple cardiovascular conditions. Their findings on HFpEF showed a 40% improvement — a magnitude of benefit that is rare for any intervention in this condition.

How GLP-1s Help the Failing Heart

The mechanism appears to involve multiple pathways working together. Excess body fat — particularly visceral fat around the heart and abdomen — drives the inflammation and metabolic dysfunction that underlie HFpEF. GLP-1 medications address this through weight loss, direct anti-inflammatory effects, and improved metabolic signaling.

As Muthiah Vaduganathan, a cardiologist at Brigham and Women's, explained: "Excess weight and adiposity and obesity are the fundamental drivers of why these conditions are not only occurring but also progressing over time." GLP-1 medications target those fundamental drivers more effectively than any previous therapy. Harvard Gazette

Beyond weight loss, GLP-1 receptors on cardiac cells may produce direct protective effects on heart muscle stiffness and function — though the precise mechanisms are still being investigated.

The Broader Cardiovascular Picture

This HFpEF finding adds to an already impressive cardiovascular profile for GLP-1 medications: the SELECT trial showed a 20% reduction in major adverse cardiovascular events, including a 28% reduction in heart attacks. The drugs have also shown benefits for peripheral artery disease, stroke prevention, and blood pressure reduction.

As Krüger told the Harvard Gazette: "It's just astonishing how many indications those medications seem to be effective for."

Ready to Get Started?

These verified telehealth providers offer GLP-1 programs with medical oversight and home delivery:

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content or provider selection.